A Systematic Review of MicroRNAs in Nasal NK/T-Cell Lymphoma: Diagnostic, Prognostic, and Therapeutic Perspectives
Mittal G.C. Nurani K.M. Chattu V.K. Payedimarri A.B. Clare R. Narayanan P. Găman M.-A.
December 2025Elsevier Inc.
Clinical Lymphoma, Myeloma and Leukemia
2025#25Issue 12e1127 - e1133 pp.
Nasal NK/T-cell lymphoma (NKTCL) is a highly aggressive malignancy with significant predominance with Epstein-Barr virus infection. MicroRNAs (miRNAs) have been found to be key regulators in cancer biology that influence tumorigenesis, disease progression, and immune evasion. This systematic review examines the role of miRNAs in diagnostics, prognosis, and treatment of NKTCL. PubMed and SCOPUS databases were systematically searched using the keywords “miRNAs” and “nasal lymphoma.” Duplicate removal and selection based on the inclusion criteria produced 15 studies for final inclusion. Study design, specific miRNAs under study, and their relevance to NKTCL have been extracted for this narrative synthesis. PRISMA guidelines were followed, and results were narratively synthesized. In the selected studies, miRNAs showed their utility as potential diagnostic markers. Downregulated miRNAs, including miR-15a, miR-101, and miR-342-3p, differentiated NKTCL from normal tissue, while EBV-encoded miRNAs, including miR-BART20-5p and miR-BART8, were identified as potential circulating biomarkers. Prognostically, miRNAs such as miR-223 and miR-342-3p were associated with poor survival and aggressive disease features. Therapeutically, miRNA-based interventions targeting EBV miRNAs, such as miR-BART20-5p and miR-BART9, were emphasized for their ability to modulate immune pathways and oncogenic signaling. Despite these promising reports, heterogeneity in study designs and geographic settings limits their generalization. miRNAs are emerging as key players in the treatment of NKTCL, with application in diagnosis, prognosis, and therapy. Larger, heterogeneous cohorts and the progression of miRNA-based therapeutic research should further validate such studies. This review highlights the potential of miRNA in translation into better outcomes in NKTCL patients.
Cancers , Chemotherapy , Epstein-Barr virus , Immune regulation , Neoplasm , Radiotherapy , Systematic review
Text of the article Перейти на текст статьи
Center for Evidence-based Research, Global Health Research and Innovations Canada Inc. (GHRIC), Toronto, ON, Canada
Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya
ReSTORE lab, Department of OS & OT, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
Department of Epidemiology and Biostatistics, Semey Medical University, Semey, Kazakhstan
Department of Community Medicine, Faculty of Medicine, Datta Meghe Institute of Medical Sciences (DMIMS), Wardha, India
Division of Public Health, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
Centre for Digital Health Applied Research and Technology, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India
Prasanna School of Public Health, Manipal Academy of Higher Education, Karnataka, Manipal, India
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Department of Hematology, Centre of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
Department of Cellular and Molecular Pathology, Stefan S. Nicolau Institute of Virology, Romanian Academy, Bucharest, Romania
Center for Evidence-based Research
Faculty of Health Sciences
ReSTORE lab
Department of Epidemiology and Biostatistics
Department of Community Medicine
Division of Public Health
Centre for Digital Health Applied Research and Technology
Prasanna School of Public Health
Faculty of Medicine
Department of Hematology
Department of Cellular and Molecular Pathology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026